

DALE B. SCHENK et al.  
Application No.: 09/724,288  
Page 2

70. (New) The method of claim 50, wherein the combining comprises adding antigen-associated biological entity to the medium, and contacting the medium with the phagocytic cells bearing Fc receptors.

71. (New) The method of any of claim 50, wherein the antigen-associated biological entity is provided as a tissue sample.

72. (New) The method of claim 50, wherein the antigen is the biological entity.

73. (New) The method of claim 50, wherein the tissue sample comprises an amyloid deposit.

74. (New) The method of claim 73, wherein the tissue sample is from the brain of an Alzheimer's disease patient or a mammal animal having Alzheimer's pathology.

75. (New) The method of claim 50, wherein the antigen is A $\beta$ .

76. (New) The method of claim 50, wherein the phagocytic cells are microglial cells.

77. (New) The method of claim 50, wherein the tissue sample is selected from the group consisting of a cancerous tissue sample, a virally infected tissue sample, a tissue sample comprising inflammatory cells, a nonmalignant abnormal cell growth, and a tissue sample comprising an abnormal extracellular matrix.

REMARKS

Claims 1, 48, 50, 60, 68, and 69-77 are pending. Claims 50 and 69-77 are under consideration, claims 1, 48, 60, and 68 having been withdrawn from consideration and new claims 69-77 having been added. New claims 69-77 correspond to claims 51-59, respectively, as originally filed. Thus, the addition of claims 69-77 does not add new matter.